Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

This study is testing a new investigational drug called MDX2001 in people with advanced solid tumors. This is a dose escalation and dose expansion trial — meaning researchers are first figuring out the right dose, then expanding to more patients. It is an early-phase trial focusing primarily on safety. **You may be eligible if...** - You are 18 or older - You have a confirmed advanced solid tumor cancer (any type that has spread) - You have at least one measurable tumor on scans - Your general health status is good (ECOG 0–1) - Your heart, liver, kidneys, and blood counts are functioning adequately **You may NOT be eligible if...** - You have significant heart disease - You have unresolved side effects from prior cancer treatment - You have had an organ or bone marrow transplant - You have untreated or uncontrolled brain metastases - You are HIV positive, or have active hepatitis B or C - You have received a live vaccine within 28 days of starting treatment - You are currently enrolled in another treatment trial Talk to your doctor to see if this trial is right for you.